QUEBEC CITY, June 15, 2012 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR), a
Quebec life sciences company that develops and commercializes
high-value cancer diagnostic tests, today announced that the Company
will present a review of its business strategy at the Bloom Burton &
Co. Healthcare Investor Conference on Thursday, June 21, 2012, at 9:30
AM (EDT). The Bloom Burton & Co. Healthcare Investor Conference brings
together U.S., Canadian and European investors who are interested in
the latest developments in the Canadian healthcare sector. Attendees
will have an opportunity to obtain corporate updates from the premier
Canadian public and private companies through presentations and
break-out Q&A sessions. The conference is being held in Toronto on June
More information on the Bloom Burton & Co. Healthcare Investor
Conference 2012 can be found at www.bloomburton.com
About Bloom Burton & Co.
Bloom Burton & Co. is Canada's largest and most active
healthcare-specialized investment banking group. The team of healthcare
specialists merges scientific, medical, clinical, intellectual property
and commercial expertise with a strong understanding of the capital
markets, to advise and raise capital for private and public companies.
For more information, please visit www.bloomburton.com.
DiagnoCure (TSX: CUR) is a life sciences company that develops and
commercializes high-value cancer diagnostic tests that increase
clinician and patient confidence in making critical treatment
decisions. In 2008, the Company launched the PrevistageTM GCC Colorectal Cancer Staging Test through its U.S. CLIA laboratory, and
granted the worldwide exclusive rights to this test to Signal Genetics
in June 2011. The Company has also granted a worldwide exclusive
license agreement to Gen-Probe (NASDAQ: GPRO) for the development and
commercialization of a second-generation prostate cancer test using
PCA3, DiagnoCure's proprietary molecular biomarker. Gen-Probe's
PROGENSA® PCA3 test is commercialized in Europe under CE mark and is
now approved for commercialization in Canada and the United States. For
more information, visit www.diagnocure.com.
This release contains forward‐looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual
results to differ materially from those expected. By their very nature,
forward‐looking statements are based on expectations and hypotheses and
also involve risks and uncertainties, known and unknown, many of which
are beyond DiagnoCure's control. As a result, investors are cautioned
not to place undue reliance on these forward‐looking statements. The
forward-looking statements regarding the outcome of research and
development projects, clinical studies and future revenues are based on
management expectations. In addition, the reader is referred to the
applicable general risks and uncertainties described in DiagnoCure's
most recent Annual Information Form under the heading "Risk Factors".
DiagnoCure undertakes no obligation to publicly update or revise any
forward‐looking statements contained herein unless required by the
applicable securities laws and regulations.
SOURCE DIAGNOCURE INC.
For further information:
Chief Financial Officer
Morin Public Relations
(514) 289-8688 ext. 236